Related Articles
Interleukin-2 and 13-cis retinoic acid as maintenance therapy in advanced ovarian cancer
Interleukin-2 and 13-cis retinoic acid in the treatment of minimal residual disease: A phase II study
Real‑world evaluation of the efficacy of immune checkpoint inhibitors in the treatment of metastatic breast cancer
First-line chemotherapy with docetaxel plus capecitabine followed by capecitabine or hormone maintenance therapy for the treatment of metastatic breast cancer patients
Predictive significance of T cell subset changes during ex vivo generation of adoptive cellular therapy products for the treatment of advanced non‑small cell lung cancer